Experimental shot for Cold-Triggered hives tested, but trial stopped early
NCT ID NCT06353971
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tested a single dose of a drug called briquilimab in 27 adults with chronic hives caused by cold or friction that did not improve with standard allergy pills. The main goal was to check safety and see if the drug could reduce symptoms. However, the trial was terminated early, so results are limited.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC INDUCIBLE URTICARIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Charité - University Clinic Berlin
Berlin, 12203, Germany
-
University Clinic Schleswig-Holstein
Lübeck, 23538, Germany
-
University Hospital Dresden
Dresden, 01307, Germany
-
University of Marburg
Marburg, 35043, Germany
-
University of Munster
Münster, 48149, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New pill could stop hives from scratching or cold
- New pill for chronic hives enters first human safety tests
- New drug shows promise for Long-Term control of chronic hives
- Scientists hunt for clues to better diagnose triggered hives
- New pill could tame stubborn hives
- New shot may stop hives from cold and scratching